Patents by Inventor John McCafferty
John McCafferty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932673Abstract: Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.Type: GrantFiled: July 11, 2018Date of Patent: March 19, 2024Assignee: MAXION THERAPEUTICS LIMITEDInventors: Aneesh Karatt Vellatt, John McCafferty, Sachin Badrinath Surade, Tim Luetkens, Edward William Masters, Michael Richard Dyson, Damian Colin Bell
-
Patent number: 11926818Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: GrantFiled: February 11, 2020Date of Patent: March 12, 2024Assignee: Iontas LimitedInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Patent number: 11912984Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: GrantFiled: February 11, 2020Date of Patent: February 27, 2024Assignee: Iontas LimitedInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Publication number: 20230331827Abstract: Abstract: Binding members for potassium channel Kv1.3 and their use in medicine, including for treatment of autoimmune conditions, metabolic disorders and obesity. Binding members comprise a fusion protein containing a Kv1.3-binding peptide, e.g., HsTx, ShK or KTX (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), paired with a partner domain (e.g., antibody variable domain).Type: ApplicationFiled: July 11, 2018Publication date: October 19, 2023Applicant: MAXION THERAPEUTICS LIMITEDInventors: Aneesh KARATT VELLATT, John MCCAFFERTY, Sachin Badrinath SURADE, Tim LUETKENS, Edward William MASTERS, Michael Richard DYSON, Damian Colin BELL
-
Publication number: 20230212288Abstract: The invention relates to the field of immunology and biotechnology, and also to the creation of novel effective high-molecular compounds having therapeutic properties. Variants of amino acid sequences of complementarity-determining regions (CDR) of antigen-binding fragments of a protein molecule specific to human cell CD3 receptors are proposed. The proposed CDR can be used for engineering various antigen-binding molecules, one of the essential function of which is a specific interaction with CD3-bearing cells. Bispecific molecules that specifically bind to human cell CD3 and CD19 receptors were engineered by means of the inclusion of said CDR in the composition of an antibody-like molecule intrinsically binding to the CD19 receptor.Type: ApplicationFiled: August 20, 2020Publication date: July 6, 2023Inventors: Aleksandr Aleksandrovich PISKUNOV, Svetlana Georgievna ABBASOVA, Anton Nikolaevich MOROZOV, Aleksandr Mikhailovich SHUSTER, Peter SLAVNY, Daniel GRIFFITHS, Izabela KACZYNSKA, John MCCAFFERTY, Michael DYSON
-
Patent number: 11499150Abstract: Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and/or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.Type: GrantFiled: December 5, 2018Date of Patent: November 15, 2022Assignee: Iontas LimitedInventors: John McCafferty, Rajika Perera, Michael Richard Dyson, Kothai Parthiban, Johanna Liinamaria Syrjanen
-
Patent number: 11286477Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: GrantFiled: May 1, 2015Date of Patent: March 29, 2022Assignee: Iontas LimitedInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Publication number: 20210179677Abstract: Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.Type: ApplicationFiled: July 11, 2018Publication date: June 17, 2021Applicant: IONTAS LIMITEDInventors: Aneesh KARATT VELLATT, John MCCAFFERTY, Sachin Badrinath SURADE, Tim LUETKENS, Edward William MASTERS, Michael Richard DYSON, Damian Colin BELL
-
Publication number: 20210163923Abstract: Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and/or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.Type: ApplicationFiled: December 5, 2018Publication date: June 3, 2021Applicant: IONTAS LIMITEDInventors: John MCCAFFERTY, Rajika PERERA, Michael Richard DYSON, Kothai PARTHIBAN, Johanna Liinamaria SYRJANEN
-
Publication number: 20200165596Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: ApplicationFiled: February 11, 2020Publication date: May 28, 2020Applicant: IONTAS LIMITEDInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Publication number: 20200165595Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: ApplicationFiled: February 11, 2020Publication date: May 28, 2020Applicant: IONTAS LIMITEDInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Publication number: 20200165597Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: ApplicationFiled: February 11, 2020Publication date: May 28, 2020Applicant: IONTAS LIMITEDInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Patent number: 10647766Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.Type: GrantFiled: December 11, 2015Date of Patent: May 12, 2020Assignee: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Frances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
-
Publication number: 20190256840Abstract: This invention relates to libraries of binding members that each comprise a fusion protein which contains a donor diversity scaffold domain, such as a cysteine rich protein, inserted within a recipient diversity scaffold domain, such as an antibody constant or variable domain. Libraries and methods of generating libraries are provided, along with screening methods, binding members and methods of using the binding members.Type: ApplicationFiled: January 9, 2017Publication date: August 22, 2019Applicant: IONTAS LTDInventors: Aneesh Karatt Vellatt, John McCafferty, Sachin Surade, Tim Luetkens, Edward Masters, Michael Dyson
-
Publication number: 20170362314Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.Type: ApplicationFiled: December 11, 2015Publication date: December 21, 2017Inventors: Frances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
-
Publication number: 20170073664Abstract: The invention relates to methods of producing eukaryotic cell libraries encoding a repertoire of binding molecules (“binders”), wherein the methods use a site-specific nuclease for targeted cleavage of cellular DNA to enhance site-specific integration of binder genes through endogenous cellular repair mechanisms. Populations of eukaryotic cells are produced in which a repertoire of genes encoding binders are integrated into a desired locus in cellular DNA (e.g., a genomic locus) allowing expression of the encoded binding molecule, thereby creating a population of cells expressing different binders.Type: ApplicationFiled: May 1, 2015Publication date: March 16, 2017Applicant: IONTAS LIMITEDInventors: John McCafferty, Michael Dyson, Kothai Parthiban
-
Patent number: 9150659Abstract: Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed.Type: GrantFiled: January 30, 2012Date of Patent: October 6, 2015Inventors: Gillian Murphy, Christopher Tape, John McCafferty
-
Publication number: 20150147274Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.Type: ApplicationFiled: November 30, 2012Publication date: May 28, 2015Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
-
Publication number: 20140050738Abstract: Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed.Type: ApplicationFiled: January 30, 2012Publication date: February 20, 2014Applicant: Cancer Research Technology LimitedInventors: Gillian Murphy, Christopher Tape, John McCafferty
-
Publication number: 20120129710Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.Type: ApplicationFiled: June 21, 2011Publication date: May 24, 2012Applicants: MEDIMMUNE LIMITED, MEDICAL RESEARCH COUNCILInventors: John McCafferty, Anthony Richard Pope, Kevin Stuart Johnson, Hendricus Renerus Jacobus Mattheus Hoogenboom, Andrew David Griffiths, Ronald Henry Jackson, Kasper Philipp Holliger, James David Marks, Timothy Piers Clackson, David John Chiswell, Gregory Paul Winter, Timothy Peter Bonnert